Answers are grounded in this paper and cite their sources.
Schizophrenia heterogeneity has resisted resolution for over a century, with no unifying clinical feature, biomarker, or pathogenic pathway identified. This has produced imprecise diagnosis, prognosis, and treatment, while confounding mechanistic research. Prior subtyping approaches—based on clinical phenotype, longitudinal course, age of onset, neuroimaging, physiological measures, or etiological factors—have yielded partial insights but lack established clinical utility. The Johns Hopkins Schizoaffective Disorder Precision Medicine Center of Excellence (PMCOE) brings together patients and clinicians at the Johns Hopkins Hospital and the Johns Hopkins Bayview Community Psychiatry Program with Johns Hopkins schizophrenia investigators to address this heterogeneity through stratification by treatment response, dividing patients into non-treatment-resistant (nonTRS), clozapine-responsive treatment-resistant (crTRS), and ultra-treatment-resistant (uTRS) subgroups. The term "Schizoaffective Disorder" was chosen to include schizophrenia with varying degrees of affective symptomatology, deliberately creating a broadly inclusive patient group. We hypothesize that these subtypes reflect distinct pathophysiological processes and that identifying their biological correlates will improve clinical decision-making and reveal novel therapeutic targets. The PMCOE pursues this hypothesis across four aims. Aim 1 characterizes clinical, cognitive, functional, quality-of-life, and olfactory signatures distinguishing subtypes, with preliminary data showing worse cognition and function in uTRS versus crTRS, and a temporal sequence of clozapine benefit (symptoms, then function, then quality of life). Aim 2 applies 7T structural/functional MRI—including novel measures of microvascular perfusion (iVASO) and CSF clearance (cDSC)—alongside EEG-based dynamic causal and network modeling to probe excitatory/inhibitory imbalance across subtypes. Aim 3 investigates cellular and molecular mechanisms, particularly protein homeostasis dysfunction, using patient-derived induced neurons, organoids, and extracellular vesicles, with focused study of SCHEMA-identified risk genes, including CUL1. Aim 4 leverages electronic health record data to generate validated electronic phenotypes for treatment-response subtypes and to establish a learning health system translating findings into clinical practice. By anchoring subtyping to an empirically measurable, clinically actionable outcome, the PMCOE aims to accelerate biomarker discovery for clozapine response, clarify mechanisms of treatment resistance, and transform care for individuals with schizophrenia—particularly those with ultra-treatment-resistant illness, for whom therapeutic options remain critically limited.
No takes yet. Share an insight, caveat, or question.
Margolis et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: